JMP Securities lowered the firm’s price target on Zimmer Biomet to $140 from $160 and keeps an Outperform rating on the shares following the Q3 earnings report. JMP believes Zimmer is well positioned to make meaningful steps toward the long-term strategy of its core franchises achieving “at or above market growth rates,” and management previously noted that it feels more comfortable with an 4% growth range ahead in a normal environment, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ZBH:
- Zimmer Biomet management to meet with BTIG
- Zimmer Biomet price target lowered to $149 from $172 at Baird
- Zimmer Biomet price target lowered to $119 from $152 at Wells Fargo
- Zimmer Biomet backs FY23 adjusted EPS view $7.47-$7.57, consensus $7.50
- Zimmer Biomet reports Q3 adjusted EPS $1.65, consensus $1.60